Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 5, 2014, Pages 1032-1043

  Awasthi, Niranjan ^a,c   Zhang, Changhua ^c,d   Schwarz, Anna M ^c   Hinz, Stefan ^c   Schwarz, Margaret A ^a   Schwarz, Roderich E ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY HEALTH   (United States)

^c The University of Texas Southwestern Medical Center Department of Pharmacology Dallas   (United States)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD31 ANTIGEN; PACLITAXEL; SUNITINIB; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CAPILLARY DENSITY; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG PENETRATION; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; IC 50; MONOTHERAPY; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY EFFECT; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ALBUMINS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HUMANS; MICE; PACLITAXEL; PANCREATIC NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899790508     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0361     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
3. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005;6:229-39.
4. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a reviewof adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 2007;6:609-21.
5. Rougier P, Adenis A, Ducreux M, de Forni M, Bonneterre J, Dembak M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000;36: 1016-25.
6. Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 1997;15:2414-9.
7. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803.
8. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006; 12:1317-24.
9. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703.
10. Awasthi N, Zhang C, Schwarz AM, Hinz S, Wang C, Williams NS, et al. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate- based docetaxel in experimental pancreatic cancer. Carcinogenesis 2013;34:2361-9.
11. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, et al. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs 2008;26:463-71.
12. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28:3617-22.
13. Dragovich T, Burris H III, Loehrer P, Von Hoff DD, Chow S, Stratton S, et al. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. AmJ Clin Oncol 2008;31:157-62.
14. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
15. Assifi MM, Hines OJ. Anti-angiogenic agents in pancreatic cancer: a review. Anticancer Agents Med Chem 2011;11:464-9.
16. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
17. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
18. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
19. Fujimoto K, Hosotani R, Wada M, Lee JU, Koshiba T, Miyamoto Y, et al. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 1998;34:1439-47.
20. Korc M. Pancreatic cancer-associated stroma production. Am J Surg 2007;194:S84-6.
21. Tran Cao HS, Bouvet M, Kaushal S, Keleman A,Romney E, Kim G, et al. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther 2010;9:2068-78.
22. Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. PLoS ONE 2012;7:e38477.
23. Awasthi N, Schwarz MA, Verma V, Cappiello C, Schwarz RE. Endothelial monocyte activating polypeptide II interferes with VEGFinduced proangiogenic signaling. Lab Invest 2009;89:38-46.
24. Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE. BMS- 754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther 2012;11:2644-53.
25. Schwarz RE, McCarty TM, Peralta EA, Diamond DJ, Ellenhorn JD. An orthotopic in vivo model of human pancreatic cancer. Surgery 1999;126:562-7.
26. Osgood RJ, Skipper J, Jiang P, Zimmerman S, Shepard HM, Maneval DC, Thompson CB, et al. Pegylated recombinant human hyaluronidase PH20 (PEGPH20) enhances nab-paclitaxel efficacy in BxPC-3 human pancreatic cancer xenografts [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR;
27. Cancer Res 2012;72(8 Suppl):Abstract nr 5635.
28. Zhang L, Smith KM, Chong AL, Stempak D, Yeger H, Marrano P, et al. In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia 2009;11:426-35.
29. von Baumgarten L, Brucker D, Tirniceru A, Kienast Y, Grau S, Burgold S, et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 2011; 17:6192-205.
30. Awasthi N, Schwarz MA, Schwarz RE. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy. Cancer Chemother Pharmacol 2011;68:571-82.
31. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007;6:1186-97.
32. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29:4548-54.
33. Watkins G, Martin TA, Bryce R, Mansel RE, Jiang WG. Gamma- Linolenic acid regulates the expression and secretion of SPARC in human cancer cells. Prostaglandins Leukot Essent Fatty Acids 2005; 72:273-8.
34. Volk LD, Flister MJ, Bivens CM, Stutzman A, Desai N, Trieu V, et al. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia 2008;10:613-23.
35. Konno H, Tanaka T, Matsuda I, Kanai T, Maruo Y, Nishino N, et al. Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP- 470, and mitomycin C on the growth and liver metastasis of human colon cancer. Int J Cancer 1995;61:268-71.
36. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8: 210-21.
37. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, StadlerWM,et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-8.
38. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
39. Seandel M, Shia J, Linkov I, Maki RG, Antonescu CR, Dupont J. The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects. Clin Cancer Res 2006;12: 6203-4.
40. Schwarz RE, Awasthi N, Konduri S, Cafasso D, Schwarz MA. EMAP IIbased antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer. Ann Surg Oncol 2010;17:1442-52.
41. Awasthi N, Yen PL, Schwarz MA, Schwarz RE. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. J Cell Biochem 2012;113:784-91.
42. Awasthi N, Zhang C, Hinz S, Schwarz MA, Schwarz RE. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. J Exp Clin Cancer Res 2013; 32:12.
43. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G. H. A. Clowes memorial award lecture. Cancer Res 1990;50:6130-8.
44. Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer 2013;108:1838-45.
45. Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol Cancer 2003;2:6.
46. Hayes AJ, Li LY, Lippman ME. Anti-vascular therapy: a new approach to cancer treatment. West J Med 2000;172:39-42.
47. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6:392-401.
48. Bieche I, Lachkar S, Becette V, Cifuentes-Diaz C, Sobel A, Lidereau R, et al. Overexpression of the stathmin gene in a subset of human breast cancer. Br J Cancer 1998;78:701-9.
49. Li Y, Li X, Hussain M, Sarkar FH. Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia 2004;6:158-67.
50. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trialson anti-VEGF therapy for cancer. NatClinPract Oncol 2006;3:24-40.